EAC 2020 Update in Allergy, Asthma and Immunology

August 16, 2020 to August 18, 2020

The EAC 2020 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision making concerning advancements in the diagnosis and treatment strategies for patients. Topics of discussion will include updates in diagnosis and treatment of HAE, biologics for severe asthma, allergic skin diseases, advances in peanut allergy treatments and management of penicillin and other antibiotic allergies.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Allergy Conference. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 15.5 contact hours.

Commercial Support
This activity is supported in part by independent medical education grants from CSL Behring, Stallergenes Greer and Optinose.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Prescribe optimal therapy in patients with food allergy
  2. Diagnose and manage peanut allergy
  3. Diagnose and manage eosinophilic esophagitis
  4. Diagnose and manage drug allergy
  5. Diagnose and manage hereditary angioedema
  6. Discuss current and future allergy immunotherapy treatment options for respiratory allergies
  7. Outline to the use of biologics for allergic diseases, including asthma, chronic urticaria and nasal polyps
  8. Evaluate for potential immunodeficiency
  9. Diagnose and manage patietns with mast cell activiation syndrome

 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 


 

Course summary
Available credit: 
  • 15.50 AMA PRA Category 1 Credit™
  • 15.50 Attendance
  • 15.50 CBRN
Course opens: 
08/16/2020
Course expires: 
12/31/2022
Event starts: 
08/16/2020 - 1:00pm CDT
Event ends: 
08/18/2020 - 3:00pm CDT
Add to calendar: 
Rating: 
0

EAC 2020 Update in Allergy, Asthma and Immunology
The Breakers – Palm Beach, Florida
August 16 – 18, 2020


Sunday, August 16, 2020

1:00 – 1:30    When to consider Immunologic evaluation in patients presenting with “rash”, Jennifer Leiding, MD

1:30 – 2:00    CRScNP Management in the era of biologics, Michael Blaiss, MD

2:00 – 2:15    Q & A

2:15 – 2:45    Combination ics/beta-agonist inhaler as reliever therapy: FDA vs new guidelines, Leonard Bacharier, MD

2:45 – 3:15    Chronic urticaria: Best practice for evaluation and treatment, Jonathan Bernstein, MD

3:15 – 3:30    Q & A

4:30 – 5:05    Assessing the unmet need for current and future biologics in pediatric asthma management, Leonard Bacharier, MD

5:05 – 5:40    Safety of SLIT vs. SCIT: An update on adverse events and fatalities, Russell Settipane, MD

5:40 – 6:15    Efficacy of SLIT tablets in pollen and dust mite allergy, Lawrence DuBuske, MD

6:15 – 6:30    Q & A


Monday, August 17, 2020

7:45 – 8:35    Pro: Anti-IL5 therapies are biologics of choice for severe eosinophilic asthma, Mario Castro, MD
                      Con: Anti-IL5 therapies are NOT biologics of choice for severe eosinophilic asthma, Rey Panettieri, MD

8:35 – 8:45    Q & A

8:45 – 10:00    PBL  -  A 36-year old women with repeated episodes of hives, hypotension and diarrhea.

10:00 – 10:45    Coffee Break/Visit Exhibits/Posters

10:45 – 11:00    Post PBL Case Summary, Jonathan Bernstein, MD

11:00 – 11:30    MCAS: Myths and realities, Jonathan Bernstein, MD

11:30 – 11:35     Q & A

11:35 – 12:05    Weighing the benefits and risks of peanut OIT in clinical practice, Aikaterini Anagnostou, MD

12:05 – 12:15    Q & A

1:15 – 1:45    Immunodeficiency update, Jennifer Leiding, MD

1:45 – 2:15    When to consider patch testing in atopic dermatitis, Marcella Aquino, MD

2:15 – 2:45    The Allergist’s role in the COVID-19 pandemic, Joseph Bellanti, MD

2:45 – 3:00    Q & A


Tuesday, August 18, 2020

7:45 – 8:10    Telemedicine: How has it changed clinical allergy practice, and what will the post - COVID future look like?, Justin Greiwe, MD

8:10 – 8:35    Opportunities and challenges of shared-decision making in the telemedicine era, Don Bukstein, MD

8:35 – 8:45    Q & A

8:45 – 10:00    PBL  -  An 18 -year old male with dysphagia

10:00 – 10:45    Coffee Break/Visit Exhibits/Posters

10:45 – 11:00    Post PBL Case Summary, Karen Hsu Blatman, MD

11:00 – 11:30    The role of the allergist in the multidisciplinary evaluation and management of EoE, Karen Hsu Blatman, MD

11:30 – 11:35     Q & A

11:35 – 12:05    Immediate hypersensitivity testing for drug allergies, Aleena Banerji, MD

12:05 – 12:15    Q & A

1:15 – 1:45    HAE: Guideline-based care and beyond, Aleena Banerji, MD

1:45 – 2:15    Best Practice for oral food challenges – Which patients need a challenge and when?, Justin Greiwe, MD

2:15 – 2:45    Peanut Diagnostics: A GRADE Guideline, Dana Wallace, MD

2:45 – 3:00    Q & A

3:00         Meeting adjourn

All identified conflicts of interest have been resolved.

Aikaterini Anagnostou, MD – Speaker
Disclosures: Independent Contractor/contracted research: Aimmune

Leonard Bacharier, MD – Speaker
Disclosures: Consultant/consulting fee: AstraZeneca, DBV Technologies, GlaxoSmithKline, Sanofi, Regeneron; Speaker/honoraria: AstraZeneca GlaxoSmithKline, Sanofi, Regeneron, Novartis; 

Aleena Banerji, MD – Speaker
Disclosures: Advisory Board/honorarium: Shire, CSL Behring, Biocryst, Pharming, Pharvaris, Kalvista; Research Grant/honorarium: Biocryst, Shire

Jonathan Bernstein, MD – Speaker
Disclosures: Consultant/consulting fee: ALK, AstraZeneca, Biocryst, CSL Behring, Dyax, Genentech, Novartis, Merck, Regeneron, Sanofi, Shire; Speaker/honoraria: ALK, AstraZeneca, CSL Behring, Dyax, Genentech, Novartis, Regeneron, Sanofi, Shire; Independent Contractor/contracted research: ALK, AstraZeneca, Biocryst, Boehringer Ingelheim, CSL Behring, Dyax, Genentech, Novartis, Merck, Regeneron, Sanofi, Shire, Stallergenes, Teva; Advisory Board/honorarium: ALK, AstraZeneca, Biocryst, CSL Behring, Dyax, Genentech, Novartis, Regeneron, Shire

Michael Blaiss, MD – Speaker
Disclosures: Consultant/consulting fee: Pfizer, Merck, Hycor, ALK, Greer, Sanofi, JDP Therapeutics, PMD Healthcare, DBV Technologies

Karen Hsu Blatman, MD – Speaker
Disclosures: Independent Contractor/contracted research: Takeda

Don Bukstein, MD – Speaker
Disclosures: Speaker/honorarium: AstraZeneca, Aventis, Teva, Sanofi, Regeneron, Genentech, Circassia; Independent Contractor/contracted research – Circassia

Mario Castro, MD – Speaker
Disclosures: Consultant/consulting fee: Novartis, Sanofi, Teva, Genentech; Speaker/honorarium: AstraZeneca, GlaxoSmithKline, Sanofi, Teva, Genentech, Regeneron; Research Study/consulting fee: AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Pulmatrix, Shionogi

William Corrao, MD – Planner
Disclosures: Speaker/honorarium: GlaxoSmithKline, Boehringer Ingelheim

Ray Davis, MD – Speaker
Disclosures: Consultant/consulting fee: ALK, Baxalta, Shire, Genentech, Novartis, Circassia, Takeda, DBV Technologies, Maculogix; Speaker/honorarium: DBV Technologies, Novartis

Lawrence DuBuske, MD – Speaker
Disclosures: Consultant/consulting fee: ALK, AstraZeneca, Regeneron, Sanofi, Allergy Therapeutics, Abionic; Speaker/honorarium: ALK, AstraZeneca, Novartis, Regeneron, Sanofi; Advisory Board/honorarium: ALK, AstraZeneca, Regeneron, Sanofi

Justin Greiwe, MD – Speaker
Disclosures: Speaker/honorarium: AstraZeneca, Regeneron, Sanofi; Advisory Board/consulting fee: AstraZeneca
  
Jennifer Leiding, MD – Speaker
Disclosures: Consultant/consulting fee: CSL Behring, Horizon Therapeutics; Speaker/honorarium: CSL Behring, Horizon Therapeutics
Advisory Board/consulting fee: CSL Behring, Horizon Therapeutics, Orchard Therapeutics 

Rey Panettieri, Jr., MD – Speaker
Disclosures: Consultant – Novartis, DBV Technologies; Speaker/honorarium: AstraZeneca, Genentech, Sanofi; Advisory Board//consulting fee: AstraZeneca, Medimmune, Research Institute for Fragrance Materials, Equillium, Theravance, Avillion; Independent Contractor/consulting fee: AstraZeneca, Medimmune, Research Institute for Fragrance Materials, Equillium, Genentech, Oncoarendi, Metera

Robert Settipane, MD –  Planner
Disclosures: Independent Contractor/contracted research: AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Teva, Novartis, Syneos Health, Biocryst, Avillion

Russell Settipane, MD – Planner/Speaker
Disclosures: Speaker/honorarium: ALK, Genentech, Regeneron, Teva, Pharming, Shire, Sunovion, Boehringer Ingelheim; Consultant/consulting fees: Boehringer Ingelheim, RB Health; Advisory Board/contracted research: ALK, AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, Teva, Pharming; Independent Contractor/honorarium: AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Teva, Syneos Health, Novartis, Biocryst, Avillion

Dana Wallace, MD – Speaker
Disclosures: Consultant/consulting fee: Mylan, Kaleo, Bryan; Speaker/honorarium: Optinose, ALK, Sanofi


The following have nothing to disclose:

Marcella Aquino, MD – Speaker
Joseph Bellanti, MD – Planner/Speaker
William Greisner, III, MD – Planner/Moderator/Reviewer
Katelyn Loiselle, RN – Planner 
Ginny Loiselle – Coordinator
Michael Slaughter, MD – Planner/Moderator/Reviewer
Kelli Wilson - Planner

 

 

 

 

 

 

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (EAC).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 15.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 15.50 AMA PRA Category 1 Credit™
  • 15.50 Attendance
  • 15.50 CBRN
Please login or create an account to take this course.